ArticleJournal of neuroinflammation2026
Endothelial-specific Ezh2 deficiency exacerbates blood-brain barrier dysfunction and neuroinflammation in sepsis-associated encephalopathy.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Sepsis-associated encephalopathy (SAE) is a frequent yet insufficiently understood form of acute brain dysfunction driven by systemic inflammation and neurovascular injury. Here, we identify endothelial Enhancer of Zeste Homolog 2 (Ezh2) as a key epigenetic regulator that maintains blood-brain barrier (BBB) integrity and restrains neuroinflammatory responses during sepsis. Using constitutive and inducible endothelial-specific Ezh2 knockout mice, we demonstrate that loss of Ezh2 disrupts neurovascular unit organization at baseline, characterized by reduced tight junction protein expression, diminished glucose transporter levels, altered vascular morphology, and impaired astrocytic endfoot coverage. Following cecal ligation and puncture, Ezh2-deficient mice exhibited markedly increased mortality, exacerbated cerebral edema, and severe albumin extravasation, indicating profound BBB breakdown. Neuropathological analyses revealed region-dependent neuronal degeneration and apoptosis across cortex, midbrain, and hippocampus, accompanied by reactive gliosis and microglial activation. The absence of Ezh2 further promoted robust leukocyte infiltration, including neutrophils and CD4⁺/CD8⁺ T cells, into the cortex, basal ganglia, and choroid plexus, consistent with dysregulated peripheral-central nervous system (CNS) immune communication. Transcriptomic profiling identified upregulation of inflammatory, cytokine, and cell death pathways alongside downregulation of synaptic, metabolic, and neuronal maturation programs, providing a mechanistic molecular landscape linking endothelial epigenetic dysfunction to CNS vulnerability. Collectively, these findings reveal that endothelial Ezh2 acts as a protective neurovascular gatekeeper that limits systemic inflammatory penetration into the CNS and mitigates neuroimmune activation during sepsis. This work establishes an epigenetic axis coupling BBB dysfunction to neuroinflammation in SAE and suggests that endothelial-targeted epigenetic modulation may represent a therapeutic strategy for limiting CNS injury in systemic inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.